Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 703

Results For "US"

7056 News Found

Thermo Fisher’s new facility in Bengaluru to produce reliable COVID-19 testing kits
News | February 23, 2021

Thermo Fisher’s new facility in Bengaluru to produce reliable COVID-19 testing kits

Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.


Unichem Laboratories receives ANDA approval for Apremilast Tablets
News | February 20, 2021

Unichem Laboratories receives ANDA approval for Apremilast Tablets

Apremilast tablets are indicated for the treatment of adult patients with moderate to severe plaque psoriasis .


Lupin receives approval for Droxidopa capsules
News | February 20, 2021

Lupin receives approval for Droxidopa capsules

Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness


Dr. Reddy's Laboratories launches FH Tablets in the U.S. Market
News | February 19, 2021

Dr. Reddy's Laboratories launches FH Tablets in the U.S. Market

Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.


Granules India announces approval of Potassium Chloride ER Capsules
News | February 18, 2021

Granules India announces approval of Potassium Chloride ER Capsules

Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).


Lupin launches posaconazole delayed-release tablets
News | February 18, 2021

Lupin launches posaconazole delayed-release tablets

posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.


Steady quarter with margin improvement for Glenmark: ICICI Securities
News | February 17, 2021

Steady quarter with margin improvement for Glenmark: ICICI Securities

India business grew 11.8% YoY vs mid-single digit industry growth.


Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr
News | February 15, 2021

Glenmark Q3 FY21 net profit up 30% at Rs 248 Cr

The jump in profit is due to the better performance of the API business.


Steady performance; for Alkem Laboratories: ICICI Securities
News | February 13, 2021

Steady performance; for Alkem Laboratories: ICICI Securities

The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21


Jubilant Pharmova recovers: ICICI Securities
News | February 13, 2021

Jubilant Pharmova recovers: ICICI Securities

Jubilant announced the completion of demerger of pharma and LSI business into two separate companies